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The latent membrane protein 1 (LMP-1) oncogene of Epstein-Barr virus (EBV) is believed to contribute to
the development of many EBV-associated tumors, and there is evidence that sequence variation can affect some
functions of LMP-1. Most studies have been restricted to the prototype B95.8 LMP-1 gene and genes isolated
from EBV of nasopharyngeal carcinoma (NPC) patients. Here, we analyzed the signaling functions of LMP-1
from a panel of nine EBV isolates, including representatives of four defined groups of European LMP-1
variants (groups A to D [K. Sandvej, J. W. Gratama, M. Munch, X. G. Zhou, R. L. Bolhuis, B. S. Andresen,
N. Gregersen, and S. Hamilton-Dutoit, Blood 90:323–330, 1997]) and Chinese NPC-derived LMP-1. Chinese
and group D variants activated the transcription factor NF-B two- to threefold more efficiently than B95.8
LMP-1, while Chinese, group B, and group D variants similarly activated activator protein 1 (AP-1) tran-
scription more efficiently than did B95.8 LMP-1. However, there were no amino acid substitutions in the core
binding regions for tumor necrosis factor receptor-associated adapter proteins known to mediate NF-B and
AP-1 activation. In contrast, despite sequence variation in the proposed Janus kinase 3 binding region, STAT
activation was remarkably constant among the panel of LMP-1 variants. Analysis of the induction of CD54
(intercellular adhesion molecule 1) protein expression by the LMP-1 variants showed differences that did not
correlate with either NF-B or AP-1. Therefore, while the defined sequence variant groups do correlate with
LMP-1 function, the results highlight the fact that the relationship between sequence variation and signaling
function is extremely complex. It appears unlikely that one particular amino acid substitution or deletion will
define a disease-associated variant of LMP-1.
Epstein-Barr virus (EBV) is a potent transforming agent for
human B lymphocytes, and infection of resting B cells with
EBV in culture regularly gives rise to lymphoblastoid cell lines
(LCL) sustaining a largely nonpermissive infection (44). This
growth transformation requires the cooperative action of at
least five “latent” EBV genes. One of these essential latent
genes encodes the latent membrane protein 1, which is onco-
genic in various experimental models (3, 74, 77), can enhance
cell survival through upregulation of antiapoptotic genes (17,
31, 52, 75), and is essential for continued proliferation of es-
tablished LCL (47, 55). Furthermore, LMP-1 is expressed in
the EBV-associated posttransplant lymphoproliferative disor-
ders (PTLD) in immunocompromised patients, as well as in
many EBV-associated malignancies including Hodgkin’s dis-
ease and nasopharyngeal carcinoma (NPC) (23, 32, 61, 78, 79).
LMP-1 is a transmembrane protein whose essential struc-
tural features are illustrated in Fig. 1A. A short cytosolic N
terminus of about 23 amino acids interacts with the cytoskel-
eton and is responsible for turnover of the molecule by the
ubiquitin-proteasome degradation pathway (2, 73). The six
transmembrane spanning hydrophobic domains serve to in-
duce spontaneous aggregation of LMP-1 molecules, resulting
in a constitutively active receptor molecule (27, 29). The large
cytoplasmic C terminus of LMP-1 of about 200 amino acids
binds various protein adapter molecules utilized by receptors
of the tumor necrosis factor (TNF) superfamily (11, 41, 45, 60,
66). These signaling adapter proteins bind to two regions of the
LMP-1 molecule termed C-terminal activating regions,
CTAR1 and CTAR2, which were originally identified as do-
mains responsible for activation of the NF-B transcription
factors (38, 59). CTAR1, located in the membrane proximal
region, has a core PXQXT motif at amino acids 204 to 208
which binds the TNF receptor-associated factors TRAF1,
TRAF2, TRAF3, and TRAF5 (11, 15, 66). CTAR2, located at
the extreme C terminus of the LMP-1 molecule, binds the TNF
receptor-associated death domain protein (TRADD) and the
receptor interacting protein (RIP) (19, 39, 41, 45). Recently, a
putative CTAR3 domain encompassing amino acids 275 to 330
was reported to bind Janus kinase 3 (JAK-3) (28). Through the
spontaneous aggregation of LMP-1 molecules and the associ-
ation with cytosolic adapter proteins, LMP-1 transduces a
number of cell signaling pathways, leading to activation of the
transcription factors NF-B, activator protein 1 (AP-1), and
STAT (10, 20, 28, 30, 46).
There has been considerable interest in the possibility that
specific sequence changes in LMP-1 may define more onco-
genic genotypes. While some molecular epidemiological stud-
ies have failed to establish a correlation between LMP-1 se-
quence and disease association (18, 43, 72), other studies have
identified NPC-derived LMP-1 genes as having elevated cell
* Corresponding author. Mailing address: Section of Infection and
Immunity, Department of Medicine, 2nd Floor, Tenovus Building,
University of Wales College of Medicine, Cardiff CF14 4XN, United
Kingdom. Phone: 44 (029) 20 742579. Fax: 44 (029) 20 743868. E-mail:
RoweM@cardiff.ac.uk.
9129
 o
n
 February 25, 2014 by Cardiff Univ
http://jvi.asm.org/
D
ow
nloaded from
 
9130 FIELDING ET AL. J. VIROL.
 o
n
 February 25, 2014 by Cardiff Univ
http://jvi.asm.org/
D
ow
nloaded from
 
transformation potential and decreased immunogenicity (36,
71). Furthermore, expression of LMP-1 variants in NPC cor-
relates with differences in growth pattern and the clinical
course of the disease (34, 35). Most attention has focused on
LMP-1 variants containing a deletion of 10 amino acids (amino
acids 343 to 352), adjacent to CTAR2. This del-LMP-1 variant
was originally identified in Chinese NPC tumors (13, 37) and
was subsequently detected in European cases of Hodgkin’s
disease, PTLD, and peripheral T-cell lymphomas (37, 48–50,
70). In vitro experiments suggested that the del-LMP-1 variant
has greater oncogenic potential than the prototype B95.8
EBV-derived LMP-1 (13, 37, 54). However, the significance of
the association of the del-LMP-1 variant with EBV-related
malignancies is unclear, since the incidence of EBV-associated
malignant disease in different geographical locations appears
to reflect the incidence of the del-LMP-1 variant in the corre-
sponding healthy population (43, 69). Furthermore, while the
prototype Chinese del-LMP-1 variant (Cao) and an African
NPC-derived del-LMP-1 variant are both able to induce high
levels of NF-B activation, this property does not map to the
10-amino-acid deletion itself but rather to other associated
sequence variations that are not clearly defined (8, 42, 58).
In the present study, because of the difficulty in ascribing an
altered LMP-1 phenotype to single amino acid substitutions, it
was decided to analyze the functions of a larger panel of
naturally occurring LMP-1 genes carefully selected from de-
fined groups of sequence variants. Sequence analysis of the
LMP-1 gene and promoter in 62 EBV isolates from European
individuals has allowed the definition of four main groups of
LMP-1 variants, designated groups A, B, C, and D (69). Each
of these four groups is characterized by a specific pattern of
amino acid mutations relative to B95.8 LMP-1 (Fig. 1B; Table
1). Only in group C LMP-1 variants is the 10-amino-acid se-
quence at residues 343 to 352 deleted. Interestingly, none of
the group A through D variants or the Chinese del-LMP-1
variants shows mutations in the core TRAF/TRADD/RIP
binding sequences in CTAR1 and CTAR2. However, there are
numerous mutations in the putative JAK-3-binding Box-1 and
Box-2 motifs in CTAR3 (see Fig. 1).
The main question addressed by the present study is whether
the natural sequence variation in LMP-1 correlates with the
ability to activate the transcription factors that mediate the
various biological functions of this oncogene. Previous studies
have indicated significant differences between the B95.8
LMP-1 and NPC-derived LMP-1 variants with respect to acti-
vation of NF-B (42, 58). However, there is still a need for a
more systematic analysis of a panel of well-defined LMP-1
variants, not only for the ability to activate NF-B but also for
the other transcription factors activated by LMP-1. We there-
fore compared nine different LMP-1 genes, including the pro-
totype B95.8 LMP-1 and Cao del-LMP-1 variants and repre-
sentatives of each of the defined groups A, B, C, and D.
Activation of the NF-B, AP-1, and STAT transcription fac-
tors was measured by cotransfecting expression plasmids for
each of the cloned LMP-1 genes with luciferase reporter plas-
mids regulated by response elements for these transcription
factors. We also investigated the abilities of the cloned LMP-1
variants to induce expression of intercellular adhesion mole-
cule 1 (ICAM-1, also known as CD54) in lymphocytes, since
regulation of this cellular gene by LMP-1 has recently been
shown to be dependent on new, as yet unidentified signaling
events (56). The results of the present study show that natural
sequence variation does indeed affect LMP-1 signaling poten-
tial.
MATERIALS AND METHODS
Cell lines. Jurkat is an EBV-negative T-cell lymphoma-derived cell line (9).
Eli-BL is an EBV-positive B-cell Burkitt’s lymphoma, displaying a latency I type
of infection, in which EBNA-1 is expressed but the other EBNAs and LMP-1 are
not (65). DG75 is an EBV-negative Burkitt’s lymphoma cell line (7). CRB95.8
is an LCL which was established by in vitro infection of normal B cells from an
EBV-seronegative donor with B95.8 EBV (62). A number of other EBV-trans-
formed LCLs (G23, G54, G55, G46, G50, and G64) were established by spon-
taneous outgrowth from cultures of peripheral blood lymphocytes from EBV-
positive European individuals (69); these LCLs were kindly provided by Jan
Willem Gratama, Rotterdam, The Netherlands. The NPC-7 line is a spontaneous
LCL established from the blood of a southern Chinese patient with NPC (57)
and was kindly provided by Alan Rickinson, Birmingham, United Kingdom. Cell
lines were cultured in RPMI 1640 medium supplemented with 10% fetal calf
serum and antibiotics (200 U of penicillin/ml and 200 mg of streptomycin/ml) and
were maintained at 37°C in a humidified atmosphere containing 5% CO2.
Plasmids. The mammalian expression vector pSG5-neo was produced by in-
sertion of the neomycin resistance cassette from pSV2-neo (Clontech) into the
unique XbaI site of pSG5 as a blunt-ended fragment. The green fluorescent
protein (GFP) expression vector pEGFP-N1 was purchased from Clontech. The
3Enh.B-ConALuc reporter (3Enh-Luc) has been described previously (1) and
contains three tandem repeats of the NF-B binding sites from the immuno-
globulin (Ig)  promoter upstream of a minimal conalbumin promoter. The
pAP1-Luc reporter contains seven tandem copies of an AP-1 binding element
fused to a TATA-like promoter region from the herpes simplex virus thymidine
kinase promoter (Clontech). The GRR(5)-Luc reporter contains five tandem
copies of the FcR1 gamma interferon-activated sequence upstream of a mini-
mal thymidine kinase promoter in the pBL-Luc vector (6) .
Cloning and sequencing of LMP-1 natural sequence variants. DNA was ex-
tracted from washed LCL pellets by lysing in PCR-lysate buffer (10 mM Tris-Cl
[pH 9], 1 mM EDTA, 0.5% Nonidet P-40, 0.5% Tween 20, 200 g of proteinase
K/ml) at a concentration of 107 cells/ml. The lysate was incubated for at least 3 h
at 55°C, and the proteinase K was heat inactivated at 95°C for 15 min. Phenol-
chloroform extraction was performed, followed by ethanol precipitation. For the
Cao LMP-1 gene, no LCL was available; the source of DNA for this gene was the
J124-Cao construct obtained from L.-F. Hu and coworkers (37). The LMP-1
genes were PCR amplified from the DNA using a common antisense primer
FIG. 1. Amino acid sequences of LMP-1 natural sequence variants. (A) Schematic showing some features of the structure of LMP-1 in the
plasma membrane. The boxed areas on the C terminus indicate the positions of signaling domains. (B) Alignment of the amino acid sequences
of the nine LMP-1 genes analyzed in this study. The complete sequence of B95.8 is shown in single-letter amino acid code. Only differences from
the B95.8 sequence are indicated for the other eight LMP-1 sequences. Amino acid substitutions that are shared by all members of a defined group
of variants are boxed. Unboxed amino acid substitutions are those that are present in the particular isolate studied but are not characteristic of
all members of its group. Asterisks indicate deletions. Transmembrane domain residues are indicated by “mmm” above the B95.8 sequence.
Eleven-amino-acid repeats are indicated by “repeat” above the B95.8 sequence, and their absence in the aligned sequence is indicated by a series
of slashes. The CTAR1 and CTAR2 domains are indicated by open boxes enclosing the sequences. Core motifs known to be essential for binding
of TRAF, TRADD, or RIP, and motifs reported to be potential JAK-3 binding sites, are indicated by shaded boxes enclosing those sequences. Note
that the amino acid sequence of Cao LMP-1 differs from the previously published sequence (see the text). The corrected sequence has been entered
in the GenBank database (accession number AF30442).
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(5-ACGCGTTTCTGCGGATCAGTCG-3) but different sense primers accord-
ing to the LMP-1 isolate. For PCR amplification from B95.8, G23, G54, G55, and
G46, the sense primer was 5-CTCCTGACACACTGCCCTGAG-3. For ampli-
fication from G50 and G54, the sense primer was 5-CTCCTGCCACACTACC
CTGAG-3. For amplification from NPC-7 and Cao, the sense primer was
5-CTCCTGCCACACTACCCTGAC-3.
The purified PCR products were incorporated into the pCR2.1 vector (T-A
Topo Cloning kit; Invitrogen). Each LMP-1 gene was excised from the pCR2.1
vector as an EcoRI fragment and ligated into the EcoRI site of SG5-neo. The
exception was the G23 LMP-1 gene, which was found to have an EcoRI restric-
tion site in the first intron; the G23 LMP-1 gene was therefore PCR amplified
from the pCR2.1 vector with primers incorporating additional 5 BamHI sites
and was ligated into the BamHI site of SG5-neo. The expected number of
repeats in each cloned gene was confirmed using a diagnostic PCR adapted from
the work of Khanim et al. (43). The cloned LMP-1 genes were then sequenced
with the ABI Big Dye sequencing kit (Perkin-Elmer Applied Biosystems) with
TABLE 1. Defining mutations of the group A, B, C, and D and Chinese NPC variants
Locationa Codon
Amino acid(s)b in:
Reference sequence (B95.8) Group A Group B Group C Group D Chinese NPC
N-term 3 H — — — — R
13 R — — — Q P
17 R — — — L L
18 G — — — R —
25 L — — — I I
Tm 26 G — — — L —
37 L — — — I —
43 V — — — T —
Loop out 46 D — — N N —
Tm 82 A — — G G G
84 C — — G G G
85 I L L L L L
Loop out 101 H — R — Q —
Tm 106 F Y Y Y Y Y
109 I — — — V —
122 I — L L L L
Loop in 126 L — — F F F
128 E — — — D —
129 M — I I I I
132 R — — G — —
Tm 144 F — — I I I
148 F — — — L —
150 D — — A — A
151 L — — I I I
155 I — — — M —
178 L — — — — M
C-term 186 Y — — — F —
189 Q — — P — P
192 S — — T T T
212 G S S S S S
229 S — T — — —
250–298 Repeats Variable Variable Variable Variable Variable
306 L — — — Q —
309 S — N N N N
313 S — — — P —
322 Q — D N T N
328 E Q — — — —
331 G — — — Q —
334 Q — R R — R
338 L — S S P S
343–352 GGGHSHDSGH — — Deletion — Deletion
352 H — R — N —
358 H — — — P —
366 S T T T T T
377 H — — — Nc —
a N-term, amino terminus; Tm, transmembrane; Loop in, transmembrane loop exposed to cytoplasm; Loop out, transmembrane loop exposed to outside of cell;
C-term, carboxy terminus. Substitutions in the N-term, Loop in, and C-term rows were localized to the cytoplasm.
b —, no change from the B95.8 amino acid. Substitutions relative to the B95.8 amino acid are indicated by the single-letter code.
c The H377N substitution is present in about 50% of group D variants and was present in both of the group D variants (G50 and G64) analyzed in this study.
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various primers for the SG5 vector and the LMP-1 gene to give complete
overlapping nucleotide sequences of the entire LMP-1 coding region. The B95.8
and Cao LMP-1 genes were both recloned for the present study; the results
obtained in functional assays with the newly cloned vectors reproduced our
previously published results with these LMP-1 variants, thus ruling out possible
cloning artifacts as an explanation for the different phenotypes.
Gene transfection and luciferase reporter assay. Up to 107 cells in 0.5 ml of
RPMI medium buffered with 100 mM HEPES (pH 7.2) were transfected by
electroporation using a Bio-Rad Genepulser II electroporator set to 280 V and
950 F for Jurkat and Eli-BL cells, or 270 V and 950 F for DG75 cells. The cells
were then seeded in 4 ml of fresh growth medium and cultured under normal
conditions. Transfection efficiency was typically 20 to 30% for the Jurkat cell line,
5 to 10% for the Eli-BL cell line, and 40 to 50% for the DG75 cell line.
Luciferase activity from the reporter constructs was measured at 24 h posttrans-
fection, exactly as described previously (56).
Assay for cell surface CD54 (ICAM-I) by flow cytometry. The induction of cell
surface CD54 protein in the transfected cell population was assayed by immu-
nofluorescence staining of viable cells, followed by flow cytometry using a Becton
Dickinson FACScalibur analyzer as described previously (56). Briefly, cells were
harvested 48 h after transfection and stained with a phycoerythrin (PE)-conju-
gated monoclonal antibody to human CD54. The transfected cell population was
marked by the expression of cotransfected EGFP-N1 plasmid, and this popula-
tion was gated for analysis of CD54 staining.
Detection of LMP-1 by immunoblotting. Sodium dodecyl sulfate (SDS)-poly-
acrylamide gel electrophoresis and immunoblotting were performed as described
previously (56). Briefly, cells were lysed in gel sample buffer (50 mM Tris [pH
6.8], 100 mM dithiothreitol, 2% SDS, 10% glycerol, 0.05% bromophenol blue),
sonicated, and boiled. Solubilized proteins equivalent to 2  105 cells were
separated by SDS-polyacrylamide gel electrophoresis and transferred to polyvi-
nylidene difluoride (PVDF) membranes for immunoblotting. LMP-1 was de-
tected by first incubating the membranes for 1 h with 1 g of CS.1-4/ml (63) and
then incubating for 1 h with a 1/10,000 dilution of alkaline phosphatase-conju-
gated goat anti-mouse IgG (Bio-Rad catalog no. 170-6461). Specific antibody-
protein complexes were detected using the CDP-Star (Tropix Inc.) chemilumi-
nescence reagent.
Detection of LMP-1 by immunofluorescence. Air-dried smears of transfected
DG75 cells were fixed with acetone-methanol (1:1) and then stained with 10 g
of a mouse monoclonal antibody to LMP-1 (CS.1)/ml (63), followed by fluores-
cein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (F2012; Sigma) as
described previously (64). The stained cells were visualized on a Leica DM LB
microscope.
Nucleotide sequence accession number. The corrected amino acid sequence of
Cao LMP-1 has been entered in the GenBank database (accession number
AF30442).
RESULTS
Cloning and sequencing of LMP-1 natural sequence vari-
ants. As a first step in determining whether sequence variation
affected LMP-1 signaling potential, a panel of nine LMP-1
genes was cloned into the SG5-neo expression vector. The
amino acid sequences of these nine LMP-1 genes are shown in
Fig. 1B. As references, the B95.8 LMP-1 and Cao LMP-1
genes were also recloned, sequenced, and included in this
panel. It should be noted that we have sequenced both the
recloned Cao LMP-1 gene and the original gene obtained from
L.-F. Hu and coworkers and have found discrepancies with the
published sequence (37). The corrected Cao LMP-1 sequence
(GenBank accession number AF30442) is shown in Fig. 1B.
Six of the other LMP-1 genes were cloned from spontaneous
LCL derived from healthy European individuals and were se-
lected in the knowledge that the LMP-1 genes for these indi-
viduals had been previously sequenced and classified into one
of four defined groups, A through D (69). The group A, B, C,
and D LMP-1 genes are defined on the basis of consistent
nucleotide mutations, which occur in every member of a de-
fined group. Those defining mutations which lead to amino
acid substitutions are listed in Table 1 and indicated in the
sequences shown in Fig. 1B. Excluding the variable-repeat
region (residues 250 to 298 in B95.8 LMP-1), group A variants
show 5 amino acid substitutions with respect to the B95.8
LMP-1 sequence, group B variants show 13 substitutions,
group C variants show 20 substitutions, and group D variants
show 34 substitutions (Fig. 1B). In addition to these consistent
defining mutations, other occasional mutations were observed
in different members of a group. Thus, we analyzed two rep-
resentatives of the group B variants, each having a single, but
different, additional amino acid substitution: R233I in the G54
LMP-1 and H191Q in the G55 LMP-1 (Fig. 1B). Similarly, we
analyzed two members of the group D variants; G50 and G64
share one additional substitution, H377N, and G64 also has a
second substitution, S23P, in addition to those present in all
group D variants. In this context, it should be noted that 4 of
the 5 defining changes in group A variants (I85L, F106Y, G212S,
and S366T, but not E328Q) are also found in the group B, C, and
D variants and in the two Chinese isolates (Table 1). Further-
more, like B95.8, group A variants contain a 5-amino-acid insert
in the repeat region (residues 275 to 280) which is not observed
in any other variant group (Fig. 1B). Together, these observa-
tions suggest that B95.8 is an example of a group A variant.
The NPC-7 LMP-1 gene was obtained from a southern Chi-
nese NPC patient (57). It shows only 7 amino acid substitutions
relative to the prototype Cao LMP-1, and these are mostly con-
servative changes (Fig. 1B). Together, NPC-7 and Cao share
23 substitutions relative to B95.8 (Table 1). Both NPC-7 and
Cao correspond to the “Chinese-1” subgroup of LMP-1 vari-
ants identified by Edwards et al. (18). The 10-amino-acid de-
letion (corresponding to residues 343 to 352 of B95.8) is shared
by NPC-7 and Cao, as well as by European group C variants,
represented by G46 LMP-1. Interestingly, while group C vari-
ants most closely resemble the Chinese variants in the trans-
membrane and C-terminal regions, the N-terminal regions of
these two groups are quite distinct. The N-terminal regions of
the Chinese variants show the greatest similarity to group D
European variants.
The number of 33-bp (11-amino-acid) repeats varies inde-
pendently of the defined groups. Thus, Fig. 2a shows the sizes
of PCR-amplified DNA fragments obtained, using primers
flanking the repeat sequences, from each of the nine LMP-1
genes in the SG5-neo vector. This experiment shows, for ex-
ample, that the two group B isolates, G54 and G55, have 6 and
5 repeats, respectively. Since the panel of representative
LMP-1 variant genes had been cloned into the SG5-neo vector,
which contains a heterologous simian virus 40 (SV40) pro-
moter, it was necessary to confirm expression of the correct
LMP-1 proteins.
Expression of LMP-1 natural sequence variants. SV40 pro-
moter-driven expression of the LMP-1 genes from the SG5-
neo vector was first confirmed by immunoblot analysis of pro-
teins extracted from Jurkat cells transfected with the respective
plasmids. A representative blot, probed with monoclonal anti-
bodies CS.1-4, is shown in Fig. 2B. This experiment illustrates
the expected variation in protein size, which is due to the
combined effects of the variable number of 11-amino-acid re-
peats, the presence or absence of the 5 amino acids inserted in
the 4th perfect repeat, and the presence or absence of the
10-amino-acid deletion within CTAR2 (see Fig. 1B). This
Western blot also suggests that both group B variants, G54 and
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G55, may have reduced expression relative to other variants.
However, this should be interpreted with caution, since the
LMP-1 antibodies that are reactive in Western blots are spe-
cific for peptide sequences in or around the repeat region of
the cytosolic C terminus and may be particularly affected by
sequence variation.
Antibody CS.1, which recognizes a peptide epitope at the
conserved extreme C terminus (unpublished data), is less
likely to be affected by sequence variation. By itself, this
antibody does not work well in immunoblotting (63), but it
does react well with LMP-1 in immunofluorescence staining
of fixed cell smears (Fig. 2C). Immunofluorescence staining
of G54 (Fig. 2C) and G55 (data not shown) with CS.1 did
not indicate marked differences in levels of expression. Fur-
thermore, the immunofluorescence staining revealed char-
acteristic concentration or “patching” of LMP-1 expression
in DG75 cells transfected with each of the nine variant
LMP-1 expression plasmids (Fig. 2C; also data not shown),
indicating that none of the sequence variations grossly af-
fected cellular localization. Although the levels of expres-
sion could have been quantified more accurately by inserting
antibody tag sequences into each of the cloned variants, we
were reluctant to do this because of uncertainty about the
subtle effects that the tags may have on LMP-1 function.
Instead, in the following experiments, analyses of transcrip-
tional activation of reporters were carried out by careful
titration of each variant LMP-1 plasmid in each type of
reporter assay to give dose-response curves from which op-
timal amounts of LMP-1 plasmids for each assay could be
determined.
FIG. 2. Characterization and expression of cloned LMP-1 variants. (A) Agarose gel showing differences in the number of 11-amino-acid (33-bp)
repeats detected by PCR amplification. PCR products were resolved on a 3% agarose gel with a DNA ladder, stained in an ethidium bromide
solution, and visualized with UV light. The sizes of DNA ladder fragments are given in base pairs, and the number of repeats identified by the size
of the PCR product is shown beneath each lane. The B95.8 and G23 LMP-1 genes contain 4 repeats, which corresponds to four perfect 33-bp
(11-amino-acid) repeats and the 15-bp (5-amino-acid) sequence that is deleted in all other LMP-1 variants used. (B) Immunoblot showing
expression of the LMP-1 variants from the pSG5-neo vector in transiently transfected Jurkat cells. Vector (pSG5-neo)-transfected Jurkat cells were
used as a negative control. Approximately 2  105 cells were separated on a 10% polyacrylamide gel and transferred to a PVDF membrane. LMP-1
expression was detected by probing blots with the CS.1-to-CS.4 pool of monoclonal antibodies to LMP-1, followed by an alkaline phosphatase-
based chemiluminescence detection protocol. (C) Immunofluorescence staining of LMP-1 in transiently transfected DG75 cells. DG75 cells were
transfected with 5 g of LMP-1 expression vector or empty vector. Cell smears were stained with monoclonal antibody CS.1 to the C terminus of
LMP-1 and an FITC-conjugated goat anti-mouse IgG as a secondary antibody. Images of a single cell transfected with either empty vector, B95.8
LMP-1, G54 LMP-1, or NPC-7 LMP-1 are shown.
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NF-B activation by LMP-1 natural sequence variants.
NF-B has been shown to be involved in the LMP-1-mediated
regulation of many cellular genes, e.g., upregulation of A20
(52), bcl-2 (24), c-IAP2 (33), interleukin-6 (IL-6) (21), IL-8
(20), TRAF1 (16), CD40 (16), and CD54 (56) and downregu-
lation of CD99 (53). In order to investigate the ability of our
panel of LMP-1 variants to activate NF-B, the LMP-1 expres-
sion plasmids were cotransfected with the 3Enh-Luc reporter
into the Jurkat cell line. Luciferase reporter activity was mea-
sured at 24 h postinfection. A dose-response curve for each
LMP-1 variant was obtained by transfection of a variable
amount of LMP-1 expression vector with empty vector (to a
total amount of 8 g) together with 3 g of 3Enh-Luc reporter.
Figure 3A shows results of a representative dose-response ex-
periment for three LMP-1 variants: B95.8 (group A), G50
(group D), and Cao (Chinese NPC) LMP-1. As shown in Fig.
3A, maximum activation of NF-B was typically obtained with
4 to 8 g of LMP-1 expression vector. Figure 3A also shows
that the G50 and Cao LMP-1 genes activated NF-B about 2.5-
to 3-fold more efficiently than the B95.8 LMP-1 gene. Repli-
cate titrations were performed for each of the variant LMP-1
genes. In order to compare the results of several batches of
experiments performed on separate occasions, the B95.8 gene
was included in every experiment as a reference, and the max-
imum NF-B-mediated luciferase activity was expressed rela-
tive to this reference. Figure 3B summarizes the results ob-
tained with all the LMP-1 genes studied.
Figure 3B shows that all the LMP-1 genes were able to
activate NF-B but that they fell into two sets with regard to
the degree of activation. The group D and Chinese NPC vari-
ants typically gave maximum levels of NF-B activation at least
twofold higher than those of the group A, B, or C variants. The
most striking similarity between the amino acid sequences of
group D LMP-1 and the Chinese NPC LMP-1 lies in the N
terminus, where these two variant groups share substitutions at
3 residues (R13Q/P, R17L, and L25I) relative to all other
variant groups. These data therefore suggest that sequence
variation in the cytosolic N terminus can influence the effi-
ciency with which LMP-1 activates NF-B. Next, we ques-
tioned whether the same pattern of enhanced signaling would
be observed for other transcription factors activated by LMP-1.
AP-1 activation by LMP-1 natural sequence variants. Many
of the cellular genes regulated by LMP-1 contain enhancer
elements for AP-1 transcription factors, although the direct
involvement of LMP-1-activated AP-1 in transcriptional regu-
lation has not been well studied. Nevertheless, it is clear that
LMP-1 can activate AP-1 through a c-Jun N-terminal kinase
(JNK) pathway, via the TRADD/RIP binding element in
CTAR2 of the LMP-1 (22, 46). AP-1 appears to be important
for the production of IL-8 induced by LMP-1 (20) and may
contribute to the development of Hodgkin’s disease by pro-
tecting cells from apoptosis (51). NF-B can be activated via
either CTAR 1 or CTAR2, whereas AP-1 can be activated only
via the CTAR2 region of LMP-1. Therefore, it was of interest
to see whether there were differences in the efficiency with
which variants of LMP-1 activated AP-1 and whether the vari-
ants segregated in the same way as they did with regard to the
efficiency of NF-B activation.
To investigate the ability of our panel of LMP-1 variants to
activate AP-1, the LMP-1 expression plasmids were cotrans-
fected with the AP1-Luc reporter into the Jurkat cell line, and
luciferase activity was measured at 24 h. As with the NF-B
reporter experiments, a dose-response curve for each LMP-1
variant was obtained by transfection of a variable amount of
LMP-1 expression vector with empty vector (to a final amount
of 8 g) and 3 g of AP-1-Luc reporter. Figure 4A shows
results of a representative experiment for three LMP-1 genes:
B95.8 (group A), G23 (group A), and G54 (group B). The
FIG. 3. Activation of NF-B-regulated transcription by the panel of LMP-1 genes. (A) Dose-response experiment, with up to 8 g of LMP-1
expression vectors cotransfected with 3 g of the 3Enh-Luc reporter in the Jurkat cell line. The total amount of DNA per transfection was kept
constant by addition of an appropriate amount of empty vector (SG5-neo). Luciferase activity was measured after 24 h. Results of one
representative experiment, in which the B95.8, G50 (group D), and Cao (Chinese NPC) LMP-1 were transfected in parallel, are shown. (B)
Summary of the relative NF-B activity induced by each of nine variant LMP-1 genes. Results are means from at least three experiments, and the
maximum activation of NF-B by each variant gene is shown relative to the maximum activation observed with B95.8 LMP-1 in each experiment.
Error bars indicate 1 standard deviation from the mean.
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B95.8 and G23 genes followed very similar dose-response
curves, with relatively poor induction of AP-1, whereas the
G54 gene consistently gave higher AP-1 activity than the group
A variant at every dose. In contrast to the dose-response ex-
periments for NF-B activation (Fig. 3A), the dose responses
obtained with the AP-1 reporter (Fig. 4A) did not reproducibly
peak within the concentration range tested. Since reproducible
differences between the LMP-1 variants were obtained at 8 g
of LMP-1 plasmid DNA, replicate experiments were per-
formed with the whole series of LMP-1 expression vectors at
this single concentration.
Figure 4B shows the relative AP-1 activation for each
LMP-1 variant compared to B95.8 LMP-1. Even though these
data are means from at least five experiments, the low fold
activation of AP-1 above basal activity by B95.8 LMP-1 caused
the standard deviations to be relatively large (compare Fig. 4B
with Fig. 3B and 5B). Nevertheless, a reproducible pattern of
results was obtained. B95.8, group A, and group C LMP-1
variants showed relatively poor induction of AP-1 activity,
while group B, group D, and Chinese NPC variants typically
induced AP-1 activation to two- to threefold above B95.8
LMP-1 activity. The AP-1 results therefore differed from the
NF-B results shown in Fig. 3B, with the group B variants
falling into the “low” NF-B-activating set but the “high” AP-
1-activating set. There are no obvious amino acid sequence
changes common to group B, group D, and Chinese NPC
variants which could be responsible for the increase in AP-1
activation. In particular, any changes within CTAR2 that are
common to these three groups were also present in group C
LMP-1, which activates AP-1 poorly (Fig. 1B and 3). The
increased AP-1 signaling observed with the group D and NPC
variants could be due to the same changes that caused the
increased NF-B signaling, in which case different amino acid
changes may be responsible for the increased activity of group
B variants.
The results with NF-B and AP-1 in Fig. 3 and 4 illustrate
two points: (i) that sequence variation can significantly affect
the efficiency of activation of cellular transcription and (ii) the
difficulty in predicting the efficiency of transcription factor ac-
tivation from what we already know about the functional do-
mains of LMP-1 and the signal transduction mechanisms. We
therefore decided to extend the analysis to a third family of
transcription factors activated by LMP-1, the STATs, since the
reported effector domains on LMP-1, the putative JAK-3-bind-
ing motifs within CTAR3 (28), are subject to substantial vari-
ation in amino acid sequence among different groups of LMP-1
genes (Fig. 1).
STAT activation by LMP-1 natural sequence variants.
Members of the STAT family of transcription factors are con-
stitutively activated in LCLs, NPC, and Hodgkin’s disease (12,
76). LMP-1 has the ability to activate STATs (10, 28), and
many cellular genes induced by LMP-1 contain STAT-respon-
sive regulatory elements. We tested the ability of LMP-1 natural
variants to activate STATs, using the GRR(5)-Luc luciferase
reporter, which contains five copies of a gamma interferon-
activating element. LMP-1 has previously been shown to acti-
vate this reporter (10), although which particular STATs are
involved in this activation has not yet been determined.
Figure 5A shows results of a representative experiment in
which variable amounts of LMP-1 expression vector with
empty vector (to a final amount of 6 g) were cotransfected
with 10 g of GRR(5)-Luc reporter into the Eli-BL cell line.
This experiment incorporated dose responses for four LMP-1
genes: B95.8 (group A), G54 (group B), NPC-7, and Cao
(Chinese NPC). Similar results were obtained with all four
FIG. 4. Activation of AP-1-regulated transcription by the panel of LMP-1 genes. (A) Dose-response curves, with up to 8 g of LMP-1
expression vectors cotransfected with 3 g of the AP-1-Luc reporter in the Jurkat cell line. The total amount of DNA per transfection was kept
constant by addition of an appropriate amount of empty vector (SG5-neo). Luciferase activity was measured after 24 h. Results of one repre-
sentative experiment, in which B95.8, G23 (group A), and G54 (group B) LMP-1 genes were transfected in parallel samples, are shown. (B)
Relative activation of AP-1 by the LMP-1 variants. Mean AP-1 activities induced by LMP-1 sequence variants are expressed relative to that of B95.8
LMP-1 from at least five replicate transfections with 8 g of LMP-1 expression vector. Error bars indicate 1 standard deviation from the mean.
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LMP-1 genes, and maximum STAT activation was observed at
2 to 4 g of LMP-1 expression vector. Figure 5B summarizes
the results of replicate experiments with all the variant LMP-1
genes, comparing the maximum STAT activation. In contrast
to the results obtained with NF-B and AP-1 (Fig. 3B and 4B),
Fig. 5B shows that the level of STAT activation was remarkably
consistent among all LMP-1 variants. G50 LMP-1 and Cao
LMP-1 induced slightly higher STAT activation than the other
variants, but this did not reach statistical significance. The
consistency of the STAT results raises the possibility that the
activation of STAT-regulated transcription by LMP-1 is not
primarily determined by binding of JAK-3 to the Box-1 and
Box-2 motifs in CTAR3.
CD54 upregulation by LMP-1 natural sequence variants.
Previous studies on the upregulation of cell surface CD54
(ICAM-I) protein by LMP-1 have revealed additional, as yet
unidentified LMP-1-induced signaling events other than those
involving NF-B, AP-1, and STAT (56). This downstream bi-
ological readout for LMP-1 was therefore included in the
present analysis in order to detect other possible differences in
LMP-1 function due to natural sequence variation. The panel
of LMP-1 sequence variants was examined for the ability to
upregulate CD54 expression on Jurkat cells. Cells were co-
transfected with 8 g of LMP-1 plasmids and 2 g of GFP
expression plasmid, and the expression of CD54 on transfected
cells was determined at 48 h posttransfection by flow cytometry
using PE-conjugated anti-CD54 antibodies. Gating for GFP
fluorescence allowed selective analysis of the transfected sub-
population.
Figure 6 summarizes the results of three separate experi-
ments, where the induction of CD54 for each LMP-1 variant
was expressed relative to the induction obtained with B95.8
LMP-1. The group A and Chinese NPC LMP-1 variants
showed indistinguishable levels of induced CD54, while the
group B and group C LMP-1 variants showed a small but
reproducible impairment (20 to 30%) of induction relative to
B95.8. The group B LMP-1 variants (G54 and G55) contain a
number of unique amino acid substitutions that could contrib-
ute to the small reduction in CD54 induction (e.g., H352R),
but none that is shared with the group C variant (Fig. 1B).
With regard to the group C amino acid substitutions, one
(R123G) is of particular interest, since it was shown previously
FIG. 5. Activation of STAT-regulated transcription by the panel of LMP-1 genes. (A) Dose-response curves with up to 6 g of LMP-1
expression vectors cotransfected with 10 g of the GRR(5)-Luc reporter in the Eli-BL cell line. The total amount of DNA per transfection was
kept constant by addition of an appropriate amount of empty vector (SG5-neo). Luciferase activity was measured after 24 h. Results of one
representative experiment, in which the B95.8, G54 (group B), and Cao and NPC-7 (Chinese NPC) LMP-1 genes were transfected in parallel
samples, are shown. (B) Relative activation of STAT by the LMP-1 variants. Results are means from at least five experiments, and the maximum
activation of STAT by each variant gene is shown relative to the maximum activation observed with B95.8 LMP-1 in each experiment. Error bars
indicate 1 standard deviation from the mean.
FIG. 6. Relative induction of CD54 (ICAM-1) by LMP-1 variants.
Levels of CD54 protein induced in Jurkat cells by the LMP-1 sequence
variants were measured at 48 h posttransfection by immunofluorescent
staining with PE-conjugated anti-CD54 antibodies and analyzed by
flow cytometry. Transfected cells were identified and gated by expres-
sion of cotransfected GFP marker plasmid, and these cells were selec-
tively analyzed for CD54 protein expression. Results for each variant
were expressed relative to the induction of CD54-positive cells ob-
served with B95.8 LMP-1. The mean relative induction of CD54 from
three separate experiments is shown. Error bars indicate 1 standard de-
viation from the mean.
VOL. 75, 2001 TRANSCRIPTION FACTOR ACTIVATION BY LMP-1 VARIANTS 9137
 o
n
 February 25, 2014 by Cardiff Univ
http://jvi.asm.org/
D
ow
nloaded from
 
that substitution of a oppositely charged amino acid (R132E)
at this point caused reduced induction of CD54 without affect-
ing NF-B (38). The most marked difference observed in these
experiments was greater induction of CD54 by the group D
isolates, G50 and G64 (Fig. 6). Group D variants are defined as
having 35 amino acid substitutions relative to the B95.8 se-
quence. Sixteen of these 35 mutations are unique to group D
(Fig. 1B). In terms of NF-B, AP-1, and STAT activation, the
group D variants behave the same as the Chinese NPC vari-
ants. This suggests that 1 or more of the 16 unique amino acid
substitutions may be involved in regulating as yet unidentified
signaling events.
DISCUSSION
Much is known about the biological properties of LMP-1
with regard to its oncogenic potential and its effects on cell
gene expression, cell survival, cell proliferation, and immuno-
genicity. There has also been extensive study of the cell signal-
ing pathways transduced by LMP-1 to activate families of tran-
scription factors which mediate the changes in cellular
phenotype. Furthermore, constitutive activation of the NF-B,
AP-1, and STAT transcription factors, all of which are acti-
vated by LMP-1, is implicated in the development of EBV-
associated malignancy (4, 5, 10, 12, 51, 76). However, most of
our knowledge of LMP-1 signal transduction and biological
functions has been gained from studies on one prototype
LMP-1 derived from the B95.8 strain of EBV. Studies with
LMP-1 variants have been mainly restricted to analysis of del-
LMP-1 NPC-derived variants from two Chinese patients,
which have been shown to have greater oncogenic potential in
nude mice and may be less immunogenic, and from one North
African patient (13, 14, 34, 36, 42, 58, 71). It is not clear to what
extent the functions of NPC-derived del-LMP-1 variants are
shared by sequence variants from other geographical locations.
The present study, in which a panel of nine LMP-1 genes was
investigated, is an important development because it repre-
sents a more systematic analysis of the abilities of defined
groups of European and Chinese variant LMP-1 genes to ac-
tivate the NF-B, AP-1, and STAT transcription factors.
The ability of two NPC-derived LMP-1 genes to activate
NF-B more efficiently than B95.8 LMP-1 (Fig. 3) is consistent
with previous reports (42, 58). However, that the European
group D variants (G50 and G64) also have increased NF-B
signaling is a novel observation. There are just three amino
acid substitutions which are common to both group D and the
NPC group but not present in any of the other variants, and
these are all located in the cytosolic N terminus of LMP-1:
R13Q/P, R17L, and L25I (Table 1). The simplest interpreta-
tion, which assumes that the mechanism is the same for group
D and Chinese NPC variants, is that enhanced NF-B activity
is due to the shared substitutions in the N terminus. The N
terminus of LMP-1 is involved in LMP-1 turnover and the
association of LMP-1 with the cytoskeleton (2, 73). The N
terminus and the transmembrane domain of B95.8 LMP-1,
when expressed alone, have inhibitory effects on NF-B sig-
naling and activity of the LMP-1 promoter (67).
Very recently, Blake et al. reported data that were inter-
preted as demonstrating that the increased NF-B signaling of
Cao LMP-1 mapped to the transmembrane domains rather
than to the N terminus (8). Furthermore, Miller et al. mapped
five amino acid changes, in the transmembrane domains of
LMP-1, which were implicated in the increased NF-B activa-
tion induced by the C15 North African NPC LMP-1 (58).
While the C15 LMP-1 is distinct in many respects from our
group B and C variants, four of the five apparently critical
substitutions in the C15 variant (I85L, F106Y, I122L, and
M129L) are also present in our group B and C variants, which
activate NF-B to levels similar to those seen with B95.8
LMP-1 (Fig. 3B). Furthermore, mutation of each of these four
residues in B95.8 LMP-1 failed to ascribe the phenotypic dif-
ferences to any single residue (8). The remaining change in the
C15 LMP-1 variant (E128D) was found in the group D variants
but not in the Chinese NPC variants (see Table 1). Interest-
ingly, amino acid 128 is located in a cytoplasmic loop of the
transmembrane spanning domain, which has previously been
shown to influence the induction of CD54 by LMP-1 (38).
However, the significance of the E128D substitution remains
to be confirmed experimentally. Together, these data suggest
that the efficiency of NF-B activation can be influenced by
more than one type of naturally occurring amino acid substi-
tution in the N terminus and/or the transmembrane domain.
Although AP-1 has not been implicated in such a wide range
of biological functions of LMP-1 as has NF-B, it does appear
to be important in an antiapoptotic function of LMP-1 (51)
and in the induction of IL-8 by LMP-1 (20). There are reports
that LMP-1 variants can activate AP-1 with different efficien-
cies (8, 14, 25). One study reported that Cao LMP-1 was less
efficient than B95.8 LMP-1 at activating AP-1 (14), while a
second study from the same laboratory (8) produced the op-
posite result. Our results with Cao and B95.8 LMP-1 are in
agreement with the latter of these two reports (8) and with a
study from a third laboratory (25). In addition, we have iden-
tified three groups of LMP-1 variants with increased abilities to
activate AP-1 (group B, group D, and the NPC variants) rel-
ative to those of group A and group C variants (Fig. 4B).
Because AP-1 activation by LMP-1 has been mapped only to
CTAR2 (19, 45), while NF-B activation has been mapped to
both CTAR1 and CTAR2 (38), one might have predicted that
it would be easier to assign substitutions responsible for influ-
encing AP-1 activation. However, this was not the case. Anal-
ysis of the sequences of the two sets of LMP-1 variants segre-
gated on the basis of AP-1-activating ability does not obviously
implicate any particular substitution(s).
These data highlight the complexity of the signaling mech-
anisms of LMP-1 and the incompleteness of our current un-
derstanding of how LMP-1 signals. The essential core se-
quences at amino acids 204 to 208 and 379 to 284 involved in
binding TRAF, TRADD, and RIP are well defined (27, 39, 45,
66). However, relatively little is known about sequences out-
side these core domains which, while not essential, can clearly
exert a significant influence on the protein interactions neces-
sary for signal transduction. In this context it should be noted
that while CTAR1 and CTAR2 are both independently able to
activate signals, the effect is not simply additive; there appears
to be some physical cooperation between CTAR1 and CTAR2
(26). This cooperation widens the scope for mutations that
may indirectly affect the optimum binding conformation of the
LMP-1–TRAF–TRADD–RIP complexes. It also raises the pos-
sibility that the number of 11-amino-acid repeats in the C ter-
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minus could affect any physical cooperation between CTAR1
and CTAR2, although our data do not reveal any simple cor-
relation between the number of repeats and NF-B or AP-1
activation (see Fig. 2A, 3B, and 4B). The effect of sequence
variation on LMP-1 signaling will be the summation of the
effects (both positive and negative) on the overall ability to
bind and activate signaling protein complexes. If several mu-
tations are contributing to the overall effect, then it will be
difficult to pinpoint particular amino acid substitutions as being
responsible. However, by defining groups of sequence varia-
tions with distinct signaling properties, we can begin to under-
stand how natural sequence variation in LMP-1 may contribute
to the development of EBV-induced disease.
In contrast to the highly conserved nature of the core bind-
ing domains for TRAF, TRADD, and RIP, several substitu-
tions and deletions in the putative JAK-3-binding domains
have been identified by Gires et al. (28) (see Fig. 1). One might
predict that these sequence variations would have marked ef-
fects on JAK-3 and STAT activation. However, we found the
ability of all LMP-1 variants to activate STAT-dependent tran-
scription to be remarkably constant (Fig. 5). This observation
appears to be incompatible with the hypothesis that JAK-3
binding to CTAR3 is required for the STAT activation we de-
tect with the GRR(5)-Luc reporter. In addition, we have ob-
served that deletion of the CTAR3 domain does not abolish
STAT-regulated reporter transcription (P. Brennan, unpub-
lished data), while point mutations which inactivate the
CTAR1 and CTAR2 domains completely abolish STAT-regu-
lated transcription (10). The region of the LMP-1 molecule
containing CTAR3 has been shown to be dispensable for EBV-
induced transformation (40), yet the constancy of STAT acti-
vation among different LMP-1 variants (Fig. 5) suggests an
important role for STAT activation. Indeed, STATs are con-
stitutively activated in EBV-associated tumors (12, 76) and are
involved in regulating viral gene expression (12). These obser-
vations highlight the need for further studies to elucidate the
mechanisms of STAT activation by LMP-1.
Analysis of CD54 (ICAM-1) protein upregulation by the
LMP-1 variants was included in this study primarily because
there is evidence that a novel, as yet unidentified signaling
pathway is involved together with NF-B (56). The most strik-
ing result obtained with our panel of variants was that group D
variants (G50 and G64) induced 40 to 100% more CD54-
positive cells than other LMP-1 variants. This result cannot be
attributed simply to differences in NF-B-, AP-1-, and STAT-
regulated transcription, since group D and NPC variants were
indistinguishable with regard to these signaling activities but
were clearly distinct with regard to their capacity to induce
CD54. This provides more evidence in support of a further
pathway or pathways that cooperate with NF-B in the induc-
tion of CD54 by LMP-1 (56). Since group D variants have 16
unique amino acid substitutions, there are many possible se-
quence changes which could be responsible for their uniquely
efficient ICAM-1 upregulation.
Interestingly, a recent study showed group D variants to be
underrepresented in Hodgkin’s disease patients relative to the
healthy population (68). It was suggested that a mutation in the
ATF-2/CREB site in the LMP-1 promoters of group D vari-
ants, which had been shown previously to decrease promoter
activity, might decrease LMP-1 expression and thus reduce the
likelihood of developing Hodgkin’s disease. Although the ef-
fect of nucleotide sequence variation in the 5 regulatory re-
gions of the LMP-1 genes is a potentially important consider-
ation, it is worth noting that we observed no major differences
in LMP-1 levels among the spontaneous LCLs from which the
LMP-1 variants were cloned (C. A. Fielding, unpublished
data). Our new observation with CD54 raises the possibility
that the underrepresentation of the group D variants in Hodg-
kin’s disease may reflect a more immunogenic phenotype in-
duced by LMP-1 through induction of higher levels of CD54
and associated cellular genes. In this scenario, group D LMP-
1-positive cells may be more effectively eliminated by immune
responses, thus limiting the likelihood of malignant cells de-
veloping.
The results in this study show that sequence variation in
LMP-1 can alter its signaling functions. It is possible, therefore,
that sequence variation in LMP-1 could influence the etiology
of EBV-associated malignancies. The underrepresentation of
certain sequence variants in Hodgkin’s disease is consistent
with a protective effect that might include enhanced immuno-
genicity and regulation by immune responses. Other sequence
variations could enhance the oncogenic properties of LMP-1,
e.g., by enhancing the ability of LMP-1 to promote cell survival
through the induction of antiapoptotic proteins. This study has
highlighted the fact that the relationship between sequence
variation and signaling function is complex to such a degree
that it is unlikely that a particular amino acid substitution or
deletion will define a disease-associated variant of LMP-1. The
way forward in understanding the effects of sequence variation
on LMP-1 function lies not in analyzing the effects of single
amino acid changes in isolation but in refining the definition of
variant groups which correlate with the known functions of
LMP-1.
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